BioXcel Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
December 17 2020 - 7:00AM
BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI),
a clinical-stage biopharmaceutical company utilizing artificial
intelligence to identify improved therapies in neuroscience and
immuno-oncology, today announced that Dr. Vimal Mehta, Founder and
Chief Executive Officer of BTI, will present corporate updates and
plans for 2021 at the 39th Annual J.P. Morgan Healthcare Conference
on Thursday, January 14, 2021 at 8:20 AM Eastern Time.
“I am excited to share a preview of the transformative year
ahead for the Company at the Annual J.P. Morgan Healthcare
Conference,” said Vimal Mehta, Chief Executive Officer of BTI. “In
the first quarter, we are expecting to file our first New Drug
Application with the FDA for BXCL501 and report topline data from
the TRANQUILITY and RELEASE clinical studies. We believe these
expected 2021 milestones will help us deliver the full potential
and value of BXCL501 as a novel treatment for agitation across a
wide range of neuropsychiatric disorders.”
A live webcast of the presentation and accompanying presentation
materials will be accessible through the Investors section of the
Company’s website at www.bioxceltherapeutics.com. Following the
conference, the webcast will be archived on the Company’s website
for at least 30 days.
About BXCL501
BXCL501 is an investigational, proprietary, orally dissolving
thin film formulation of dexmedetomidine, a selective alpha-2a
receptor agonist for the treatment of agitation and opioid
withdrawal symptoms. BTI believes that BXCL501 directly targets a
causal agitation mechanism, and the Company has observed
anti-agitation effects in multiple clinical studies across several
neuropsychiatric disorders. BXCL501 has been granted Fast Track
Designation by the U.S. Food and Drug Administration for the acute
treatment of agitation in patients with schizophrenia, bipolar
disorders and dementia. BXCL501 has been studied in two Phase 3
trials (SERENITY I and II) for the acute treatment of agitation
associated with schizophrenia and bipolar disorders. Also, the
product is being evaluated in a Phase 1b/2 trial (TRANQUILITY) for
the acute treatment of agitation associated with dementia, and in a
Phase 1b/2 study (RELEASE) for the treatment of opioid withdrawal
symptoms. The Company also plans to initiate a Phase 2 trial in
hospitalized patients suffering from agitation associated with
delirium within the next several months.
About BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical
company focused on drug development that utilizes artificial
intelligence to identify improved therapies in neuroscience and
immuno-oncology. BTI's drug re-innovation approach leverages
existing approved drugs and/or clinically validated product
candidates together with big data and proprietary machine learning
algorithms to identify new therapeutic indices. BTI's two most
advanced clinical development programs are BXCL501, an
investigational, proprietary, orally dissolving thin film
formulation of dexmedetomidine for the treatment of agitation and
opioid withdrawal symptoms, and BXCL701, an investigational, orally
administered, systemic innate immunity activator in development for
the treatment of aggressive forms of prostate cancer and advanced
solid tumors that are refractory or treatment naïve to checkpoint
inhibitors. For more information, please
visit www.bioxceltherapeutics.com.
Forward-Looking Statements
This press release includes “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release include but are not limited to the timing and data from
clinical development initiatives and trials for BXCL501. When used
herein, words including “anticipate,” “being,” “will,” “plan,”
“may,” “continue,” and similar expressions are intended to identify
forward-looking statements. In addition, any statements or
information that refer to expectations, beliefs, plans,
projections, objectives, performance or other characterizations of
future events or circumstances, including any underlying
assumptions, are forward-looking. All forward-looking statements
are based upon BTI's current expectations and various assumptions.
BTI believes there is a reasonable basis for its expectations and
beliefs, but they are inherently uncertain.
BTI may not realize its expectations, and its
beliefs may not prove correct. Actual results could differ
materially from those described or implied by such forward-looking
statements as a result of various important factors, including,
without limitation, its limited operating history; its incurrence
of significant losses; its need for substantial additional funding
and ability to raise capital when needed; its limited experience in
drug discovery and drug development; its dependence on the success
and commercialization of BXCL501 and BXCL701 and other product
candidates; the failure of preliminary data from its clinical
studies to predict final study results; failure of its early
clinical studies or preclinical studies to predict future clinical
studies; its ability to receive regulatory approval for its product
candidates; its ability to enroll patients in its clinical trials;
undesirable side effects caused by BTI’s product candidates; its
approach to the discovery and development of product candidates
based on EvolverAI is novel and unproven; its exposure to patent
infringement lawsuits; its ability to comply with the extensive
regulations applicable to it; impacts from the COVID-19 pandemic;
its ability to commercialize its product candidates; and the other
important factors discussed under the caption “Risk Factors” in its
Quarterly Report on Form 10-Q for the quarterly period ended
September 30, 2020, as such factors may be updated from time to
time in its other filings with the SEC, which are accessible on the
SEC’s website at www.sec.gov and the Investors section of our
website at www.bioxceltherapeutics.com.
These and other important factors could cause
actual results to differ materially from those indicated by the
forward-looking statements made in this press release. Any such
forward-looking statements represent management’s estimates as of
the date of this press release. While BTI may elect to update such
forward-looking statements at some point in the future, except as
required by law, it disclaims any obligation to do so, even if
subsequent events cause our views to change. These forward-looking
statements should not be relied upon as representing BTI’s views as
of any date subsequent to the date of this press release.
Contact Information:BioXcel Therapeutics,
Inc.www.bioxceltherapeutics.com
Investor Relations:John
Grazianojgraziano@troutgroup.com1.646.378.2942
Media:Julia Deutschjdeutsch@troutgroup.com1.646.378.2967
BioXcel Therapeutics (NASDAQ:BTAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioXcel Therapeutics (NASDAQ:BTAI)
Historical Stock Chart
From Apr 2023 to Apr 2024